// App-Quantinova.ai

2388 : Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.

Researchers

Presenter

  • Todd A. Alonzo

Principal Investigators

  • Laura Winter

  • Kathleen Glick

  • Patti Byron

  • Laura E Francisco

  • Robert S Lavey

  • Stella M. Davies

  • Franklin O. Smith

  • Alan S. Gamis

  • Soheil Meshinchi

  • Robert B. Gerbing

  • Michael R. Loken

  • Laura Pardo

  • Richard Aplenc

  • Lillian Sung

  • Susana C. Raimondi

  • Betsy A. Hirsch

  • Samir Kahwash

Medical Centers

  • Department of Paediatrics, Division of Emergency Medicine, The Hospital for Sick Children, Toronto, ON, Canada

  • Children's Oncology Group, Monrovia, CA

  • Division of Laboratory Medicine, University of Minnesota Medical Center-Fairview, Minneapolis, MN

  • Stanford University Medical Center,

  • Oncology/Hematology/BMT, British Colombia Children's Hospital, Vancouver, BC, Canada

Locations

  • United States

  • Canada

Companies

  • Hematologics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • microRNA-155

  • Nucleophosmin 1

  • CCAAT enhancer binding protein alpha

  • White Blood Cell

  • WT1 Transcription Factor

Drug/Treatment

  • miR155

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved